Juli DeGraw
12Patents
3h-index
10Co-inventors
53Inventor score
Filing activity: May 13, 2002 → Jan 13, 2012
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7842501B2 | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease | Chemistry; Metallurgy | 22 | Active |
| US8124408B2 | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies | Human Necessities | 10 | Active |
| US8357533B2 | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies | Human Necessities | 3 | Active |
| US8084256B2 | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease | Chemistry; Metallurgy | 2 | Active |
| US8133728B2 | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease | Chemistry; Metallurgy | 0 | Active |
| US9222071B2 | Cell therapy method for the treatment of tumors | Chemistry; Metallurgy | 0 | Active |
| US7811816B2 | Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell | Chemistry; Metallurgy | 0 | Expired |
| US8106153B2 | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease | Chemistry; Metallurgy | 0 | Active |
| US7172900B2 | Isolated CD8+T lymphocytes specifically cytotoxic for a disease causing target cell | General | 0 | Revoked |
| US8133972B2 | IgE antigenic peptides | Chemistry; Metallurgy | 0 | Active |
| US8084253B2 | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease | Chemistry; Metallurgy | 0 | Active |
| US8133726B2 | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.